Listed and unlisted Adverse Events

Clinical research is always delayed. Why? Patient recruitment is cited as the reason across the industry. This partly happens because the efforts put forth by Sponsors & CROs are often put together with less than ideal effort and forethought. Many people in charge of trials are o ... Show More

Patient retention is a thing that often gets overlooked. Yet, it can be one of the largest reasons contributing to you losing patients in your trials, your practice and in your care. Luckily there are some quick and easy fixes Heather and I share. 

Being persuasive is important in any facet of life. Everyone has to “sell” something every day. This means selling why you should be selected for that promotion, why your kid should listen to you, or why you should go eat somewhere over another suggested place. This applies to cl ... Show More

<p>Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.</p><p>Why GLP-1 Drugs Are in Demand </p><p ... Show More

<p>Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus.&nbsp;</p><p>This week, we’re dropping an episode of Brian Goldman’s White Coat, Black Art podcast into our feed.</p><p>We thought you might find the topic interesting. In Canada, "reminde ... Show More

<p>Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ... Show More

What did the inventor of the mRNA technology say about the mandating medicines and the political scapegoating of those who are hesitant against these mandates? What really happened at the public FDA hearing more than a week ago? Are the mandated stabs safe for us? What are some p ... Show More

Novartis CEO Vas Narasimhan talks about transforming the pharmaceutical giant into an innovative medicines company. He speaks on "The David Rubenstein Show: Peer-to-Peer Conversations". This interview was recorded February 15 in New York.See omnystudio.com/listener for privacy in ... Show More